Cover image for Biotech investing : every investor's guide
Biotech investing : every investor's guide
McCamant, Jim.
Personal Author:
Publication Information:
Cabridge, Mass. : Perseus, [2002]

Physical Description:
x, 195 pages ; 24 cm
Format :


Call Number
Material Type
Home Location
Item Holds
HD9999.B442 M38 2002 Adult Non-Fiction Central Closed Stacks

On Order



Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam.In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.

Author Notes

Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.

Reviews 1

Library Journal Review

Editor of the Medical Technology Stock Letter since the mid-1980s, McCamant uses his experience to provide a broad and deep overview of this exciting juncture of science and commerce. He focuses on why he thinks, from an investor's perspective, that now is such a propitious time to get into the market. Chapters cover a history of the field, how to invest, a state-of-the-art summary of biotechnology, patents and the clinical review process, and the future of biotechnology. Pharmaceutical companies, as opposed to strictly research companies, are particularly well situated to benefit from biotech advances, as they have both the research infrastructure and the capital to last through the long and expensive process of clinical studies. McCamant also includes a chapter on his investment philosophy that is succinct, logical, and itself worth the price of the book. Strongly recommended for academic and public libraries serving an investment public. Patrick J. Brunet, Western Wisconsin Technical Coll. Lib., LaCrosse Wheelan, Charles. Naked Economics: Undressing the Dismal Science. (c) Copyright 2010. Library Journals LLC, a wholly owned subsidiary of Media Source, Inc. No redistribution permitted.